Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
This stock's bull case is 'clearly stronger today than yesterday': analyst
March 27, 2026 7:00 PM EDTShares of one biotechnology name drew fresh attention after new clinical data strengthened the outlook for its siRNA-targeting programs, according to a note from Bernstein.
Analyst William Pickering said the early readouts by Sarepta Therapeutics in DM1 and FSHD showed encouraging signals despite limited disclosures.
He wrote that what they did present looks better than we had expected, noting that the... More
